Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus

Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill, Richard A. Furie, William Stohl, W. Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Z. John Zhong, William W. Freimuth, Michelle Petri

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing). Methods. Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label continuation study (n = 296). Disease activity was analyzed in patients with active SLE at baseline of the initial study. Biomarker and SLE medication changes were evaluated, and adverse events (AE) were monitored throughout the study. Results. Total belimumab exposure over 7 years (double-blind and open-label periods): 1746 patient-years. SLE Responder Index (SRI) response rates at Week 52 in autoantibody-positive patients: placebo, 29%; belimumab, 46% (p <0.05). In the continuation study, 57% of autoantibody- positive patients had an SRI response by Year 2 and 65% by Year 7; severe flares occurred in 19% with placebo and 17% with belimumab during the first year, with the annual rate declining to 2%-9% during years 2-7. Anti-dsDNA autoantibodies in patients positive for them at baseline had a progressive decline of 40%-60% from baseline over 2-7 years with belimumab. Corticosteroid use decreased over time with ≥ 50-55% reduction in median dose during years 5-7. Serious and overall annual AE rates, including infections, were generally stable or decreased during 7-year treatment. Conclusion. Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years. [ClinicalTrials.gov numbers: NCT00071487 and NCT00583362] (First Release Nov 1 2013; J Rheumatol 2014;41:300.7; doi:10.3899/jrheum.121368).

Original languageEnglish (US)
Pages (from-to)300-309
Number of pages10
JournalJournal of Rheumatology
Volume41
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Systemic Lupus Erythematosus
Safety
Placebos
Autoantibodies
Therapeutics
belimumab
Adrenal Cortex Hormones
Biomarkers
Infection

Keywords

  • Belimumab
  • Selena-sledai
  • SLE responder index
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. / Ginzler, Ellen M.; Wallace, Daniel J.; Merrill, Joan T.; Furie, Richard A.; Stohl, William; Chatham, W. Winn; Weinstein, Arthur; McKay, James D.; McCune, W. Joseph; Zhong, Z. John; Freimuth, William W.; Petri, Michelle.

In: Journal of Rheumatology, Vol. 41, No. 2, 02.2014, p. 300-309.

Research output: Contribution to journalArticle

Ginzler, EM, Wallace, DJ, Merrill, JT, Furie, RA, Stohl, W, Chatham, WW, Weinstein, A, McKay, JD, McCune, WJ, Zhong, ZJ, Freimuth, WW & Petri, M 2014, 'Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus', Journal of Rheumatology, vol. 41, no. 2, pp. 300-309. https://doi.org/10.3899/jrheum.121368
Ginzler, Ellen M. ; Wallace, Daniel J. ; Merrill, Joan T. ; Furie, Richard A. ; Stohl, William ; Chatham, W. Winn ; Weinstein, Arthur ; McKay, James D. ; McCune, W. Joseph ; Zhong, Z. John ; Freimuth, William W. ; Petri, Michelle. / Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. In: Journal of Rheumatology. 2014 ; Vol. 41, No. 2. pp. 300-309.
@article{f56a9c450c1e4a60adae05d84184ffea,
title = "Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus",
abstract = "Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing). Methods. Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label continuation study (n = 296). Disease activity was analyzed in patients with active SLE at baseline of the initial study. Biomarker and SLE medication changes were evaluated, and adverse events (AE) were monitored throughout the study. Results. Total belimumab exposure over 7 years (double-blind and open-label periods): 1746 patient-years. SLE Responder Index (SRI) response rates at Week 52 in autoantibody-positive patients: placebo, 29{\%}; belimumab, 46{\%} (p <0.05). In the continuation study, 57{\%} of autoantibody- positive patients had an SRI response by Year 2 and 65{\%} by Year 7; severe flares occurred in 19{\%} with placebo and 17{\%} with belimumab during the first year, with the annual rate declining to 2{\%}-9{\%} during years 2-7. Anti-dsDNA autoantibodies in patients positive for them at baseline had a progressive decline of 40{\%}-60{\%} from baseline over 2-7 years with belimumab. Corticosteroid use decreased over time with ≥ 50-55{\%} reduction in median dose during years 5-7. Serious and overall annual AE rates, including infections, were generally stable or decreased during 7-year treatment. Conclusion. Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years. [ClinicalTrials.gov numbers: NCT00071487 and NCT00583362] (First Release Nov 1 2013; J Rheumatol 2014;41:300.7; doi:10.3899/jrheum.121368).",
keywords = "Belimumab, Selena-sledai, SLE responder index, Systemic lupus erythematosus",
author = "Ginzler, {Ellen M.} and Wallace, {Daniel J.} and Merrill, {Joan T.} and Furie, {Richard A.} and William Stohl and Chatham, {W. Winn} and Arthur Weinstein and McKay, {James D.} and McCune, {W. Joseph} and Zhong, {Z. John} and Freimuth, {William W.} and Michelle Petri",
year = "2014",
month = "2",
doi = "10.3899/jrheum.121368",
language = "English (US)",
volume = "41",
pages = "300--309",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus

AU - Ginzler, Ellen M.

AU - Wallace, Daniel J.

AU - Merrill, Joan T.

AU - Furie, Richard A.

AU - Stohl, William

AU - Chatham, W. Winn

AU - Weinstein, Arthur

AU - McKay, James D.

AU - McCune, W. Joseph

AU - Zhong, Z. John

AU - Freimuth, William W.

AU - Petri, Michelle

PY - 2014/2

Y1 - 2014/2

N2 - Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing). Methods. Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label continuation study (n = 296). Disease activity was analyzed in patients with active SLE at baseline of the initial study. Biomarker and SLE medication changes were evaluated, and adverse events (AE) were monitored throughout the study. Results. Total belimumab exposure over 7 years (double-blind and open-label periods): 1746 patient-years. SLE Responder Index (SRI) response rates at Week 52 in autoantibody-positive patients: placebo, 29%; belimumab, 46% (p <0.05). In the continuation study, 57% of autoantibody- positive patients had an SRI response by Year 2 and 65% by Year 7; severe flares occurred in 19% with placebo and 17% with belimumab during the first year, with the annual rate declining to 2%-9% during years 2-7. Anti-dsDNA autoantibodies in patients positive for them at baseline had a progressive decline of 40%-60% from baseline over 2-7 years with belimumab. Corticosteroid use decreased over time with ≥ 50-55% reduction in median dose during years 5-7. Serious and overall annual AE rates, including infections, were generally stable or decreased during 7-year treatment. Conclusion. Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years. [ClinicalTrials.gov numbers: NCT00071487 and NCT00583362] (First Release Nov 1 2013; J Rheumatol 2014;41:300.7; doi:10.3899/jrheum.121368).

AB - Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n = 449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n = 177 currently ongoing). Methods. Patients (n = 345) who completed a double-blind, placebo-controlled, 52-week study of belimumab 1, 4, or 10 mg/kg and 24-week extension of belimumab (placebo switched to 10 mg/kg; belimumab same dose or switched to 10 mg/kg) could receive belimumab 10 mg/kg in an open-label continuation study (n = 296). Disease activity was analyzed in patients with active SLE at baseline of the initial study. Biomarker and SLE medication changes were evaluated, and adverse events (AE) were monitored throughout the study. Results. Total belimumab exposure over 7 years (double-blind and open-label periods): 1746 patient-years. SLE Responder Index (SRI) response rates at Week 52 in autoantibody-positive patients: placebo, 29%; belimumab, 46% (p <0.05). In the continuation study, 57% of autoantibody- positive patients had an SRI response by Year 2 and 65% by Year 7; severe flares occurred in 19% with placebo and 17% with belimumab during the first year, with the annual rate declining to 2%-9% during years 2-7. Anti-dsDNA autoantibodies in patients positive for them at baseline had a progressive decline of 40%-60% from baseline over 2-7 years with belimumab. Corticosteroid use decreased over time with ≥ 50-55% reduction in median dose during years 5-7. Serious and overall annual AE rates, including infections, were generally stable or decreased during 7-year treatment. Conclusion. Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years. [ClinicalTrials.gov numbers: NCT00071487 and NCT00583362] (First Release Nov 1 2013; J Rheumatol 2014;41:300.7; doi:10.3899/jrheum.121368).

KW - Belimumab

KW - Selena-sledai

KW - SLE responder index

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84893626020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893626020&partnerID=8YFLogxK

U2 - 10.3899/jrheum.121368

DO - 10.3899/jrheum.121368

M3 - Article

VL - 41

SP - 300

EP - 309

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -